Shawn Malone

ORCID: 0000-0001-5497-3455
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Advanced Radiotherapy Techniques
  • Glioma Diagnosis and Treatment
  • Hormonal and reproductive studies
  • Radiopharmaceutical Chemistry and Applications
  • Brain Metastases and Treatment
  • Meningioma and schwannoma management
  • Cancer, Lipids, and Metabolism
  • Vascular Malformations Diagnosis and Treatment
  • Effects of Radiation Exposure
  • Medical Imaging Techniques and Applications
  • Bladder and Urothelial Cancer Treatments
  • Health Systems, Economic Evaluations, Quality of Life
  • Radiomics and Machine Learning in Medical Imaging
  • Advances in Oncology and Radiotherapy
  • Cancer Diagnosis and Treatment
  • Statistical Methods in Clinical Trials
  • Multiple Myeloma Research and Treatments
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Intracranial Aneurysms: Treatment and Complications
  • Advanced Proteomics Techniques and Applications
  • Radiation Dose and Imaging
  • Lung Cancer Research Studies
  • Management of metastatic bone disease

Ottawa Hospital
2016-2025

University of Ottawa
2015-2025

Ottawa Regional Cancer Foundation
2006-2024

ISS International (South Africa)
2021-2024

Queen's University
2013-2024

Population Services International
2023

Ottawa Hospital Research Institute
2015-2023

Population Services International
2023

University Hospitals Seidman Cancer Center
2021

McMaster University
2020

Purpose: Androgen deprivation therapy is a common treatment in men with prostate cancer that may cause fatigue, functional decline, increased body fatness, and loss of lean tissue. These physical changes can negatively affect health-related quality life. Resistance exercise help to counter some these side effects by reducing elevating mood, building muscle mass, fat. Methods: In two-site study, 155 who were scheduled receive androgen for at least 3 months after recruitment randomly assigned...

10.1200/jco.2003.09.534 article EN Journal of Clinical Oncology 2003-04-29

Radiotherapy for prostate cancer (PCa) may cause unfavorable changes in fatigue, quality of life (QOL), and physical fitness. We report results from the Prostate Cancer Exercise Versus Normal Treatment study examining effects 24 weeks resistance or aerobic training versus usual care on QOL, fitness, body composition, prostate-specific antigen, testosterone, hemoglobin, lipid levels men with PCa receiving radiotherapy.Between 2003 2006, we conducted a randomized controlled trial Ottawa,...

10.1200/jco.2007.15.4963 article EN Journal of Clinical Oncology 2008-12-09

We evaluated whether the timing of fatal myocardial infarction (MI) was influenced by administration androgen suppression therapy (AST).The study cohort comprised 1,372 men who were enrolled onto three randomized trials between February 1995 and June 2001. In trials, randomly assigned to receive radiation with 0 versus 3 6, 8, or 6 months AST. Fine Gray's regression used determine clinical factors associated time MI, estimates MI calculated using a cumulative incidence method. When comparing...

10.1200/jco.2006.09.3369 article EN Journal of Clinical Oncology 2007-06-09

Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation after radiotherapy may improve quality of life and delay hormone resistance. We assessed overall survival with intermittent versus continuous in a noninferiority randomized trial.

10.1056/nejmoa1201546 article EN New England Journal of Medicine 2012-08-29

Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT postoperative after radical prostatectomy is unclear.

10.1016/s0140-6736(24)00548-8 article EN cc-by The Lancet 2024-05-16

Three small retrospective studies have suggested that patients undergoing continuous androgen deprivation (CAD) superior survival and time to progression if lower castrate levels of testosterone (< 0.7 nmol/L) are achieved. Evidence from prospective large has been lacking.The PR-7 study randomly assigned experiencing biochemical failure after radiation therapy or surgery plus CAD intermittent deprivation. The relationship between in the first year cause-specific (CSS) androgen-independent...

10.1200/jco.2014.58.2973 article EN Journal of Clinical Oncology 2015-03-03

This phase II study was designed to determine the efficacy of mammalian target rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients newly diagnosed glioblastoma.Patients were randomized concurrent adjuvant temozolomide or without (10 mg). The primary endpoint progression-free survival (PFS) secondary endpoints overall (OS) treatment-related toxicities.A total 171 deemed eligible for this study. Patients receive experienced...

10.1093/neuonc/nox209 article EN Neuro-Oncology 2017-10-30

10.1016/s0360-3016(00)00603-9 article EN International Journal of Radiation Oncology*Biology*Physics 2000-08-01

This prospective Phase II study was undertaken to evaluate intermittent androgen suppression as a form of therapy in men with localized prostate cancer who failed after they received external beam irradiation.Patients demonstrated rising serum prostate-specific antigen (PSA) level radiotherapy and were without evidence distant metastasis accepted into the study. Treatment each cycle consisted cyproterone acetate given lead-in for 4 weeks, followed by combination leuprolide acetate, which...

10.1002/cncr.21989 article EN Cancer 2006-06-16

Androgen deprivation with medical castration has been the mainstay treatment for metastatic prostate cancer. However, there are several drawbacks to prolonged androgen deprivation, including development of tolerance (loss dependence) and adverse effects on quality life. In mice tumor models dependence, followed by re-exposure androgens before progression preserved dependence. The possible value this strategy studied in human Several phases 2 3 clinical studies suggest that intermittent can...

10.1097/01.ogx.0000426493.20419.c0 article EN Obstetrical & Gynecological Survey 2013-01-01

Dose-escalated radiotherapy (RT) with androgen-deprivation therapy (ADT) is a standard definitive treatment of localized prostate cancer (LPCa). The optimal sequencing these therapies unclear. Our phase III trial compared neoadjuvant versus concurrent initiation ADT in combination dose-escalated RT (PRT).Patients newly diagnosed LPCa Gleason score ≤ 7, clinical stage T1b to T3a, and prostate-specific antigen < 30 ng/mL were randomly allocated for 6 months starting 4 before (neoadjuvant...

10.1200/jco.19.01904 article EN Journal of Clinical Oncology 2019-12-12

<h3>ABSTRACT</h3> <h3>Introduction:</h3> Gender disparities persist across the HIV care continuum in sub-Saharan Africa. Men are tested, linked, and retained at lower rates than women. experience more treatment interruptions, resulting higher of virological failure increased mortality. Peer support is an approach to improving men's engagement retention treatment. We assessed uptake early among men 'Coach Mpilo' peer pilot project South <h3>Methods:</h3> conducted a from March 2020 September...

10.9745/ghsp-d-21-00498 article EN cc-by Global Health Science and Practice 2022-02-11
Coming Soon ...